Siga Technologies (NASDAQ:SIGA – Get Free Report) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Insider and Institutional Ownership
55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 2.0% of Siga Technologies shares are owned by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Siga Technologies and 4D Molecular Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Siga Technologies | 43.22% | 35.23% | 31.06% |
| 4D Molecular Therapeutics | -174,314.17% | -47.27% | -42.39% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Siga Technologies | $138.72 million | 3.51 | $59.21 million | $1.02 | 6.66 |
| 4D Molecular Therapeutics | $40,000.00 | 13,354.14 | -$160.87 million | ($3.75) | -2.49 |
Siga Technologies has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Siga Technologies and 4D Molecular Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
| 4D Molecular Therapeutics | 1 | 1 | 8 | 0 | 2.70 |
4D Molecular Therapeutics has a consensus price target of $33.25, indicating a potential upside of 255.61%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Siga Technologies.
Volatility and Risk
Siga Technologies has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Receive News & Ratings for Siga Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siga Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
